



(51) International Patent Classification:

C07C 245/02 (2006.01) C07C 245/08 (2006.01)
C07C 245/06 (2006.01) C09B 44/02 (2006.01)

(21) International Application Number:

PCT/US2024/026552

(22) International Filing Date:

26 April 2024 (26.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/498,708 27 April 2023 (27.04.2023) US

(71) Applicant: **KIORA PHARMACEUTICALS PTY LTD**
[AU/AU]; Suite 201, 697 Burke Road, Camberwell, VIC,
3124 (AU).

(72) Inventor; and

(71) Applicant (for EG only): **STREM, Brian** [US/US]; 332
Encinitas Blvd, Suite 102, Encinitas, California 92024 (US).

(72) Inventors: **SPERL, Stefan**; Stauraczgasse 7/15, 1050
Wien (AT). **DANIELS, Eric**; Suite 201, 697 Burke Road,
Camberwell, VIC, 3124 (AU).

(74) Agent: **LOZAN, Vladimir S.** et al.; KNOBBE,
MARTENS, OLSON & BEAR, LLP, 2040 Main Street,
14th Floor, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS




FIG. 1

(57) Abstract: The present disclosure provides a method of treating a human subject suffering from a retinal disorder, the method comprising administering to the eye of the subject via intravitreal injection a composition comprising a compound of formula (I) as described herein.